Article info

A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
  1. Correspondence to Dr C Keywood, Addex Pharma SA, Plan-les-Ouates, CH-1228 Switzerland; charlotte.keywood{at}addexpharma.com
View Full Text

Citation

Keywood C, Wakefield M, Tack J
A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease

Publication history

  • Revised April 19, 2009
  • Accepted April 21, 2009
  • First published May 20, 2009.
Online issue publication 
August 11, 2009

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.